Overview

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Status:
Completed
Trial end date:
2020-04-06
Target enrollment:
Participant gender:
Summary
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Covance Laboratories, Inc
Parexel
PRA Health Sciences
Q2 Solutions
Treatments:
Dapagliflozin